Overview

The Use of Low Molecular Weight Heparin in Traumatic Brain Injury

Status:
Completed
Trial end date:
2005-08-01
Target enrollment:
Participant gender:
Summary
To study the safety and efficacy of early administration of Low Molecular Weight Heparin to patients with traumatic brain injury.
Phase:
Phase 4
Details
Lead Sponsor:
Hennepin Healthcare Research Institute
Minneapolis Medical Research Foundation
Collaborator:
Aventis Pharmaceuticals
Treatments:
Dalteparin
Enoxaparin
Heparin
Heparin, Low-Molecular-Weight